Analysis of fatal adverse drug events encountered in the ED

Recently published research from Italy was conducted to describe the characteristics of adverse drug events (ADEs) with a fatal outcome encountered in the ED setting, including the drugs involved, the frequency of the events and an estimate of the preventability of...

COVID19 and remdesivir reactions.

Remdesivir has been the focus of much attention in the context of the COVID-19 pandemic. A recent examination of the WHO VigiBase® has focused on Adverse Drug Events (ADEs) amongst COVID-19 patients. 1086 ADEs were reported from the 439 individual case reports up to...

Polypill delivers reduced cardiovascular events

The merits and drawbacks of so-called “polypills” continue to be debated. Researchers have recently assessed the effects of this approach using a multi-component strategy that included a statin, antihypertensives and aspirin to reduce the risk of...